1
Article
OCU calls for more use of biosimilar medicines
The OCU calls in this article to increase the use of biosimilar drugs in the National Health System given their proven quality, efficacy and safety, their special contribution to the efficiency of drug spending and their role in greater patient access to treatments. It also highlights the variability in use between the different Autonomous Communities and suggests the profit-sharing model, recently implemented in Extremadura, as a possible mechanism to promote greater use.
Organization of Consumers and Users
https://www.ocu.org/salud/medicamentos/informe/medicamentos-biosimilares
2
Document
Early Treatment: the role of biosimilars
This document, promoted by BioSim, addresses how the introduction of biosimilar medicines can promote "Early Treatment" strategies with biological medicines, provided that the evidence shows a clinical benefit for patients. The scientific societies of Hematology and Hemotherapy, Rheumatology, Clinical Pharmacology, Hospital Pharmacy, Digestive Pathology, Nephrology, Community Pharmacy and the Spanish Working Group on Corhn's Disease and Ulcerative Colitis and the Council have participated in the document. General of Official Colleges of Pharmacists.
The panel of experts, based on a previous reading based on a bibliographical review on Early Treatment, discussed the impact of biosimilars on ET in its different specialties. Among some of the conclusions, it stands out that the improvement of the cost-effectiveness ratio in biological treatments when the biosimilar molecule appears should give rise to a review of the recommendations of the clinical practice guidelines, as well as the development of clinical studies that provide evidence on the benefit that can be reported to patients betting on TE strategies.
Spanish Association of Biosimilar Medicines
https://biosim.es/documentos/Early-treatment-el-papel-de-los-medicamentos-biosimilares.pdf
3
ADIEX
Biosimilars in arthritis adalimumab, etanercept and infliximab
Farmacéuticos premieres the 2nd season of the YouTube channel of video advice on "Biosimilars and Pharmacy" given the success of the first season. Biosimilars used in different pathologies such as arthritis, cancer, psoriasis, Crohn's disease, diabetes or thrombosis will be some of the topics that will be addressed in this second season. The first in this series is the Biosimilars in Arthritis video advice, in which the active ingredients infliximab, etanercept and adalimumab are discussed: in which indications they are used, the different administration devices, etc.
CGCOF, Medicine Television and BioSim
https://www.youtube.com/watch?v=x8VCrzeBMZ0
4
Scientific article
Cost per responder of adalimumab versus methotrexate biosimilars in patients with psoriasis: a real-life experience
This Italian study shows that the cost-effectiveness of biosimilar adalimumab is comparable to that of subcutaneous methotrexate in a group of more than 700 patients with moderate to severe psoriasis. The authors indicate that the reduced cost of biosimilar medicines makes them a more accessible therapeutic option and they can also be introduced earlier in the treatment of moderate to severe psoriasis, this early treatment can modify the course of the disease and prevent the development of psoriasis. psoriasic arthritis.
JOURNAL OF DERMATOLOGICAL TREATMENT
https://pubmed.ncbi.nlm.nih.gov/37272368/
5
News
Europe authorizes two biosimilar drugs of the orphan drug eculizumab
The recent marketing authorization, by the European Commission, of two eculizumab biosimilar medicines brings to 76 the biosimilar medicines approved in the European territory. These last two approvals also represent a milestone as they are the first biosimilars of an orphan drug. Eculizumab biosimilar will be indicated for paroxysmal nocturnal hemoglobinuria, a rare, dangerous, acquired blood disorder during which unpredictable episodes of red blood cell breakdown occur and the bone marrow stops producing new blood cells and clots. The commercialization of these biosimilars will have a substantial impact on pharmaceutical spending but also on patient access.